BioMarin Pharmaceutical Inc. entered into a Share Purchase Agreement on August 17, 2026, to acquire Alesta Therapeutics B.V. for an upfront cash payment of $275 million and up to $215 million in future development and regulatory milestones. The transaction is expected to close in the third quarter of 2026 and will provide BioMarin with ALE1, a clinical-stage oral small molecule therapy for hypophosphatasia currently in Phase 1/2a trials. Alesta will spin out all non-ALE1 assets to a new entity prior to closing, meaning no Alesta employees will transfer to BioMarin. The company intends to fund the acquisition with cash on hand and expects to provide updated full-year 2026 guidance after the close. BioMarin Pharmaceutical Inc. is a global rare disease biotechnology company focused on developing medicines for genetically defined conditions.
